138 related articles for article (PubMed ID: 19765296)
41. A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib.
González Manzano R; Martínez Navarro E; Eugenieva E; Fernández Morejón FJ; Farré J; Brugarolas A
Clin Transl Oncol; 2008 Jul; 10(7):442-4. PubMed ID: 18628075
[TBL] [Abstract][Full Text] [Related]
42. A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Zaborowska-Szmit M; Kowalski DM; Piórek A; Krzakowski M; Szmit S
Pharmacol Rep; 2016 Dec; 68(6):1140-1148. PubMed ID: 27588390
[TBL] [Abstract][Full Text] [Related]
43. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.
Bilgin B; Sendur MAN; Yucel S; Celik E; Ozyukseler DT; Ayhan M; Basoglu T; Ilhan A; Akdeniz N; Gulmez A; Dogan I; Aktas BY; Gurbuz M; Koca S; Paydas S; Tatli AM; Cinkir HY; Alan O; Erol C; Hizal M; Kut E; Menevse S; Sakalar T; Taskaynatan H; Deniz GI; Karaagac M; Avci O; Sen E; Karatas F; Akinci MB; Dede DS; Demir A; Demirkazık A; Oksuzoglu B; Kilickap S; Yumuk F; Yalcin B
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2145-2152. PubMed ID: 33433657
[TBL] [Abstract][Full Text] [Related]
44. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Chang MH; Ahn HK; Lee J; Jung CK; Choi YL; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2011 Jan; 117(1):143-51. PubMed ID: 20803614
[TBL] [Abstract][Full Text] [Related]
45. Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
Argiris A; Hensing T; Yeldandi A; Patel S; Raji A; Sturgis C; Masters G; Gooding W; Pins M; Kolesar J
J Thorac Oncol; 2006 Jan; 1(1):52-60. PubMed ID: 17409827
[TBL] [Abstract][Full Text] [Related]
46. EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
van Zandwijk N; Mathy A; Boerrigter L; Ruijter H; Tielen I; de Jong D; Baas P; Burgers S; Nederlof P
Ann Oncol; 2007 Jan; 18(1):99-103. PubMed ID: 17060486
[TBL] [Abstract][Full Text] [Related]
47. Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.
Murray S; Karavasilis V; Bobos M; Razis E; Papadopoulos S; Christodoulou C; Kosmidis P; Fountzilas G
J Exp Clin Cancer Res; 2012 Sep; 31(1):77. PubMed ID: 22992338
[TBL] [Abstract][Full Text] [Related]
48. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Takeda M; Okamoto I; Nakagawa K
Lung Cancer; 2015 Apr; 88(1):74-9. PubMed ID: 25704957
[TBL] [Abstract][Full Text] [Related]
49. Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Zenke Y; Yoh K; Matsumoto S; Umemura S; Niho S; Ohmatsu H; Goto K; Ohe Y
Clin Lung Cancer; 2016 Sep; 17(5):412-418. PubMed ID: 26944770
[TBL] [Abstract][Full Text] [Related]
50. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Costa DB; Nguyen KS; Cho BC; Sequist LV; Jackman DM; Riely GJ; Yeap BY; Halmos B; Kim JH; Jänne PA; Huberman MS; Pao W; Tenen DG; Kobayashi S
Clin Cancer Res; 2008 Nov; 14(21):7060-7. PubMed ID: 18981003
[TBL] [Abstract][Full Text] [Related]
51. Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Urata Y; Katakami N; Morita S; Kaji R; Yoshioka H; Seto T; Satouchi M; Iwamoto Y; Kanehara M; Fujimoto D; Ikeda N; Murakami H; Daga H; Oguri T; Goto I; Imamura F; Sugawara S; Saka H; Nogami N; Negoro S; Nakagawa K; Nakanishi Y
J Clin Oncol; 2016 Sep; 34(27):3248-57. PubMed ID: 27022112
[TBL] [Abstract][Full Text] [Related]
52. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Yang Z; Hackshaw A; Feng Q; Fu X; Zhang Y; Mao C; Tang J
Int J Cancer; 2017 Jun; 140(12):2805-2819. PubMed ID: 28295308
[TBL] [Abstract][Full Text] [Related]
53. Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Gadgeel SM; Ali S; Philip PA; Ahmed F; Wozniak A; Sarkar FH
Cancer; 2007 Dec; 110(12):2775-84. PubMed ID: 17948911
[TBL] [Abstract][Full Text] [Related]
54. Clinical factors associated with treatment outcomes in EGFR mutant non-small cell lung cancer patients with brain metastases: a case-control observational study.
Chen YH; Chen YF; Chen CY; Shih JY; Yu CJ
BMC Cancer; 2019 Oct; 19(1):1006. PubMed ID: 31655564
[TBL] [Abstract][Full Text] [Related]
55. Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Tanaka K; Hata A; Kaji R; Fujita S; Otoshi T; Fujimoto D; Kawamura T; Tamai K; Takeshita J; Matsumoto T; Monden K; Nagata K; Otsuka K; Nakagawa A; Tachikawa R; Otsuka K; Tomii K; Katakami N
J Thorac Oncol; 2013 Jul; 8(7):892-8. PubMed ID: 23591159
[TBL] [Abstract][Full Text] [Related]
56. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
[TBL] [Abstract][Full Text] [Related]
57. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
58. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Kashiwabara K; Semba H; Fujii S; Tsumura S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):705-710. PubMed ID: 28258422
[TBL] [Abstract][Full Text] [Related]
59. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Fukuoka M; Wu YL; Thongprasert S; Sunpaweravong P; Leong SS; Sriuranpong V; Chao TY; Nakagawa K; Chu DT; Saijo N; Duffield EL; Rukazenkov Y; Speake G; Jiang H; Armour AA; To KF; Yang JC; Mok TS
J Clin Oncol; 2011 Jul; 29(21):2866-74. PubMed ID: 21670455
[TBL] [Abstract][Full Text] [Related]
60. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Chung CH; Seeley EH; Roder H; Grigorieva J; Tsypin M; Roder J; Burtness BA; Argiris A; Forastiere AA; Gilbert J; Murphy B; Caprioli RM; Carbone DP; Cohen EE
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):358-65. PubMed ID: 20086114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
